Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey

Basit Öğe Kaydı
dc.contributor.authorYozgat, Ayça Koca
dc.contributor.authorYaralı, Neşe
dc.contributor.authorÖzbek, Namık Yaşar
dc.contributor.authorLeblebisatan, Göksel
dc.contributor.authorŞaşmaz, Hatice İlgen
dc.contributor.authorAkbayram, Sinan
dc.contributor.authorÖzel, Simge Çınar
dc.date.accessioned2021-01-14T18:21:59Z
dc.date.available2021-01-14T18:21:59Z
dc.date.issued2020
dc.description.abstractObjective: Immune thrombocytopenia (ITP) is a rare autoimmune disease and hematologic disorder characterized by reduced platelet counts that can result in significant symptoms, such as bleeding, bruising, epistaxis, or petechiae. The thrombopoietin receptor agonist eltrombopag (EPAG) is a second-line agent used to treat chronic ITP purpura in adults and children. Materials and Methods: The present retrospective study evaluated the efficacy, safety, and side effects of EPAG treatment in pediatric patients with acute refractory and chronic immune thrombocytopenia, particularly focusing on iron-deficiency anemia. Results: The diagnosis was chronic ITP in 89 patients and acute refractory ITP in 16 patients. The mean age of patients was 9.5±4.5 years (minimum-maximum: 1.2-18 years) at the beginning of EPAG treatment. The overall response rate was 74.3% (n=78). The mean time for platelet count of ?50x109/L was 11.6±8 weeks (range: 1-34 weeks). The treatment was stopped for 27 patients (25.7%) at an average of 6.8±9 months (range: 1-38 months). The reason for discontinuation was lack of response in 18 patients, nonadherence in 4 patients, and hepatotoxicity in 2 patients. Response to treatment continued for an average of 4 months after cessation of EPAG in 3 patients.Conclusion: Results of the current study imply that EPAG is an effective therapeutic option in pediatric patients with acute refractory and chronic ITP. However, patients must be closely monitored for response and side effects during treatment, and especially for iron deficiency.en_US
dc.identifier.citationKoca Yozgat A, Leblebisatan G, Akbayram S, Çınar Özel S, Karakaş Z, Erduran E, Yılmaz Ş, Koçak Ü, Ünal Ş, Özdemir GN, Albayrak M, Zengin E, Oymak Y, Bör Ö, Çakmaklı HF, Söker M, Gürlek Gökçebay D, Tokgöz H, Malbora B, Karaman S, Celkan T, Şaşmaz İ, Yaralı N, Ören H, Ünüvar A, Özbek NY. Outcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkey. Turk J Haematol. 2020 Aug 28;37(3):139-144.en_US
dc.identifier.doi10.4274/tjh.galenos.2020.2019.0380
dc.identifier.endpage144en_US
dc.identifier.issn1300-7777
dc.identifier.issn1308-5263
dc.identifier.issue3en_US
dc.identifier.pmid32181630
dc.identifier.scopus2-s2.0-85090080214
dc.identifier.scopusqualityQ3
dc.identifier.startpage139en_US
dc.identifier.trdizinid380843
dc.identifier.urihttps://doi.org/10.4274/tjh.galenos.2020.2019.0380
dc.identifier.urihttps://app.trdizin.gov.tr/makale/TXpnd09EUXpNdz09
dc.identifier.urihttps://hdl.handle.net/20.500.12587/13964
dc.identifier.volume37en_US
dc.identifier.wosWOS:000564138800001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakTR-Dizin
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.relation.ispartofTurkish Journal of Hematology
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleOutcomes of Eltrombopag Treatment and Development of Iron Deficiency in Children with Immune Thrombocytopenia in Turkeyen_US
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
TJH_37_3_139_144.pdf
Boyut:
215.34 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu
Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WOS İndeksli Yayınlar Koleksiyonu